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IN THE BRAIN, estrogens have long been known tocontrol reproductive functions1 via activation of
their cognate receptors (estrogen receptors [ERs])
expressed at high levels in the hypothalamus. More
recently, however, several studies have shown that ERs
are widely expressed in the central nervous systems of
both mammalian sexes.2–5 Together with the molecu-
lar evidence of ER distribution throughout the brain,
functional investigations proved that estrogen is
involved in the control of a large number of functions
independent from sexual behavior6: to cite some,
estrogens have been shown to widely influence neuro-
transmission,7–10 to regulate the differentiation of
selected subsets of neurons,11 to influence memory,12
and to sustain social13 and affective14 behaviors.
Following the appearance of these results, interest has
grown in ERs as potential targets for treatments of
neurologic and neurodegenerative diseases, but signif-
icant advances in the field have been hampered by
methodological limitations. In fact, no tools have been
developed so far to detect the activation profile of ERs
in brain in real time that would allow us to perform a
functional examination of ER activation.
Recently, our laboratory successfully developed a
reporter mouse model for the study of the activation of
ERs under physiologic conditions and/or pharmaco-
logic stimulation, the ERE-Luc model (ERE = estro-
gen-responsive element).15,16 In this mouse, the trans-
gene carries the luciferase reporter gene driven by an
estrogen-responsive promoter and is flanked by insula-
tor sequences, which enable ubiquitous and hormone-
regulated expression of the reporter gene, as shown in
previous reports.15,16 Photinus pyralis luciferase was
chosen as a reporter for our mouse model because of
its well-known utility to register specific cell functions
in space and time when given its substrate luciferin. It
is also the reporter system best suited to small-animal
imaging because it generates photons in the absence of
exogenous excitatory stimuli, has very high enzymatic
efficiency, and has a short half-life, which is indispen-
sable to studying the progression of biologic processes
in time.17–19 The ERE-Luc model was instrumental in
obtaining a comprehensive view of ER transcriptional
activity in all peripheral organs during the estrous
cycle and provided novel insights on the mechanisms
triggering ER transcriptional activity16,20 when studied
either by biochemical assay evaluation of luciferase
expression levels or by optical imaging examination of
living animals.
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Abstract
Estrogen receptors have long been known to be expressed in several brain areas in addition to those directly involved in the
control of reproductive functions. Investigations in humans and in animal models suggest a strong influence of estrogens on
limbic and motor functions, yet the complexity and heterogeneity of neural tissue have limited our approaches to the full
understanding of estrogen activity in the central nervous system. The aim of this study was to examine the transcriptional
activity of estrogen receptors in the brain of male and female mice. Exploiting the ERE-Luc reporter mouse, we set up a novel,
bioluminescence-based technique to study brain estrogen receptor transcriptional activity. Here we show, for the first time,
that estrogen receptors are similarly active in male and female brains and that the estrous cycle affects estrogen receptor activ-
ity in regions of the central nervous system not known to be associated with reproductive functions. Because of its repro-
ducibility and sensitivity, this novel bioluminescence application candidates as an innovative methodology for the study and
development of drugs targeting brain estrogen receptors.
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The aim of the present study was to investigate the
extent to which the estrous cycle differentially modu-
lates ER activity in reproductive and nonreproductive
areas and the extent to which ER activation in male
brain differs from ER activation in the same areas of
female brain. Therefore, we developed a functional
method to precisely localize and quantify ER transcrip-
tional activity in mouse brain, enabling the quantitative
measurement of luciferase activity in selected brain
regions. With this technique, we could observe for the
first time that the estrous cycle significantly influences
ER activity in brain areas, such as limbic areas, not
related to reproduction, and that ER activity is quite
sustained in the brains of male and female mice.
Materials and Methods
Animals
All animal protocols were approved by the
Institutional Animal Care and Use Committee at the
Department of Pharmacological Sciences of the
University of Milan and were in accordance with the
European legislation. ERE-Luc mice on the C57BL/6
background were generated and bred at Harlan
(Harlan Italy s.r.l., Correzzana, Milan). Mice were
maintained in a 12-hour light-dark cycle and housed
one to four per cage with food and water ad libitum.
For this study, we used heterozygous males and
females of 2 to 4 months of age. The phase of the
reproductive cycle in the females was assessed by vagi-
nal lavages, which were air-dried and stained with the
May-Grünwald and Giemsa methods (MGG Quick
Stain Kit, Bio-optica, Milan, Italy) following the pro-
tocol provided by the manufacturer.
To avoid infections owing to intracerebroventricu-
lar (ICV) injections of luciferase and ICI, animals were
treated subcutaneously (SC) with 5 µL/g/die of the
antibiotic Baytril (0.1%, Bayer) for 3 days before
experimentation.
Animals were maintained with the diet Mucedola
4RF21 (Settimo Milanese, Italy); 1 week prior to the
experiment, animals were shifted to the estrogen-free
AIN93M (Mucedola).
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For anesthesia, mice were injected SC with 50 µL of a
solution of ketamine (1.7 mg/kg, Ketavet 50, Gellini,
Italy) and xylazine (90 µg/kg, Rompum, Bayer, Italy).
ICV injections on anesthetized animals were done
according to specific stereotaxic coordinates (bregma,
–0.25 mm; lateral, 1 mm; depth, 2.25 mm) by the use
of a Hamilton syringe rotated on the coronal plate
about 3˚ from the orthogonal position, as previously
described.21 Mice were killed by cervical dislocation
20 minutes after ICV injection of 3 µL of the luciferin
aqueous solution (beetle luciferin potassium salt, 25
mg/mL; Promega, Madison, WI,). Brains were rapidly
dissected and sectioned by means of a “brain matrix”
(adult mouse, coronal and sagittal, 1 mm spacing; Ted
Pella, Redding, CA). Sections were immediately visual-
ized by the Night Owl imaging unit (Berthold
Technologies, Bad Wildbad, Germany) consisting of a
Peltier cooled charge-coupled device (CCD) slow-scan
camera equipped with a 25 mm/f 220 0.95 lens locat-
ed in a light-tight chamber. Grayscale images of the
sections were first taken with dimmed light. Photon
emission was measured in a 15-minute exposure time.
Pseudocolor images associated with photon emission
were generated by a Night Owl LB981 image proces-
sor and transferred via video cable to a PCI frame
grabber using WinLight software (version 32,
Berthold Technologies). For colocalization of the bio-
luminescent photon emission, grayscale and pseudo-
color images were merged using WinLight version 32
software (color code from low to high photon emis-
sion: blue, green, red, yellow, and white).
Luminescence of the brain slices was expressed as the
integration of photon emission per time unit (cts/s); to
be able to compare the extent of photon emission in
brain nuclei characterized by a different area, data
were expressed as cts/s/mm2. Photon emission in
selected brain areas was quantified by means of a grid
generated with the aid of a brain atlas.22
Luciferase Enzymatic Assay
Selected brain regions were manually dissected, imme-
diately frozen, and stored at –80˚C. For the biochemi-
cal assay, tissues were homogenized by TissueLyser
(Quiagen, Hilden, Germany) using 300 µL of the phos-
phate lysis buffer (pH 7.8 containing 100 mM KPO4, 1
mM dithiothreitol, 4 mM ethylene glycol tetraacetic
acid, 4 mM ethylenediaminetetraacetic acid) and put-
ting a stainless steel bead in each 1.2 mL polyethylene
microtube (StarLab, UK). The homogenates were cen-
trifuged (5900 rpm for 30 minutes at 4˚C), and 20 µL
of the supernatant was transferred to a white opaque
96-well plate for luminescence quantification by the
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luminometer [Veritas, Turner Biosystems, Sunnyvale,
CA] for an integration time of 10 seconds after auto-
matically injecting 100 µL of luciferase assay reagent
(10 mM luciferin, 1 M dithiothreitol, 200 mM adeno-
sine triphosphate dissolved in buffer solution). Light
measurements were recorded by the luminometer soft-
ware GloMax (Promega Corp., Madison, WI). Protein
concentrations in the supernatants were measured
using the Bradford Protein Assay Kit (Pierce, Rockford,
IL) following the manufacturer’s protocols and ana-
lyzed using a EM680 microplate reader (BioRad
Laboratories, UK). The luminescence data, normalized
over the protein content of each sample, were finally
expressed as relative light units (RLUs) per microgram
of protein.
Pharmacologic Treatments
17β-Estradiol (E2, 50 µg/kg; Sigma, Italy) was admin-
istered in 100 µL of corn oil by SC injection 6 hours
before luciferin administration.
Because of its low blood-brain barrier penetrability
and short half-life, the full antagonist of the estrogen
receptor ICI 182,780 (1.3 µg/kg; Tocris, UK) was
injected ICV twice, 27 and 10 hours before luciferin
administration. Each injection contained 1.5 µL (1.3
µg/kg) of the ICI 182,780 solution (0.05 M in ethanol
98% v/v). The ER antagonist was kindly provided by
Zeneca (Basiglio, Milan, Italia). Controls were inject-
ed with vehicle.
Statistical Analysis
All statistical differences were calculated using
GraphPad software Prism5 (GraphPad Software Inc.,
San Diego, CA), setting the critical alpha level at 95%
and choosing the two-tailed test, since we were not
expecting the relationships to be directional.
In the experiment for the evaluation of the effects
of ICI 182,780 and E2 treatments on brain luciferase
activity, reported in Figure 1, we used the unpaired t-
test to compare the independent groups of samples (n
= 8 for control, n = 6 for for E2, and n = 6 for ICI
182,780). Calculated p values are as follows: control
versus E2 (whole slices): 1 p = .0260, 2 p = .0033, 3 p
< .0001, 4 p = .0032, 5 p = .0061, 6 p = .0019, 7 p =
.0202, 9 p = .0171, 10 p = .0067, 11 p = .0080; con-
trol versus ICI 182,780 (whole slices): 2 p = .0032, 3
p = .0138, 4 p = .0055, 5 p = .0005, 6 p = .0030, 7 p
= .0006, 8 p = .0020, 9 p < .0001, 10 p < .0001, 11 p
= .0232; control versus E2 (brain areas): motor cortex
(MCx) p = .0294, piriform cortex (PyrCx) p = .0105,
caudate putamen (CPu) p = .0358, thalamus (Tha) p =
.0388; control versus ICI 182,780 (brain areas): MCx
p = .0356, parietal cortex (PCx) p = .0017, CPu p =
.0316, Hyp p = .0031, hippocampus (Hipp) p = .0086,
Tha p = .0111, arcuate nucleus (Arc) p = .0007, amyg-
dala (Amy) p = .0002, nucleus accumbens (Acb) p =
.0228. Differences are significant for p < .05.
In Figure 2, the levels of luciferase activity in the
brains of female mice during the four estrous cycle
phases, associated with different levels of circulating
E2, were compared using one-way analysis of variance
followed by a Bonferroni post hoc test (n = 6 for
metestrus, n = 4 for diestrus, n = 6 for proestrus, n = 5
for estrus). Exact p values were calculated using
SigmaStat 3.5 software (Systat Software Inc.,
Richmond, CA); p values are as follows (only signifi-
cant values are reported): metestrus versus proestrus:
Hyp p = .009, Arc p = .023, septal nuclei (Sn) p = .036;
diestrus versus proestrus: Arc p = .022, Sn p = .035,
Amy p = .012; proestrus veresus estrus: Arc p = .026.
Differences are significant for p < .05.
In Figure 3, statistical analysis was obtained by
unpaired t-test; calculated p values are as follows (only
significant values are reported): male versus female
proestrus: PyrCx p = .0075, Sn p = .0012, Tha p <
.0001, Arc p = .0002; female diestrus versus female
proestrus: Sn p = .0122, Hyp p = .0234, Tha p =
.0148, Arc p = .0310.
Results
Procedure Standardization
To obtain a functional portrait of ER activation in brain
using luciferase bioluminescence, we set up a new pro-
cedure consisting of the preparation of brain slices from
control mice or from mice treated as requested by the
experiment and given luciferin as a substrate of the
reporter. Traditional imaging techniques cannot be
applied to the study of the central nervous system
because of a series of methodological limitations.
Among these, luciferin has very low permeability to the
blood-brain barrier; the skull prevents bioluminescence
to be efficiently detected by the CCD camera device,
and no three-dimensional reconstruction of the brain is
allowed, which makes it impossible to correctly attrib-
ute signals to the respective emitting areas.
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Therefore, to overcome its low blood-brain barrier
permeability, the hydrophilic substrate luciferin was
administered by ICV injection; then, for brain imag-
ing, mice were euthanized, and brains were dissected,
sliced in 11 sections using a brain matrix (Figure 4A),
and exposed to a CCD camera for the detection of
photon emission.
To define the dose of substrate ensuring enzyme
saturation, male ERE-Luc mice were injected ICV with
3 µL of a solution containing increasing concentra-
tions of luciferin (8.8, 26.5, and 79.7 µg/µL saline).
The extent of photon emission was measured 20 min-
utes after luciferin injection. Figure 4B indicates that
20 minutes after ICV injection, the substrate appeared
to have diffused throughout the brain and that the
26.5 µg/µL solution was providing the best signal to
noise ratio (Figure 4C). To better evaluate the time
necessary to obtain full distribution of the substrate,
we carried out a time course study; ERE-Luc male
mice were injected ICV with luciferin and euthanized
after 10, 20, 40, or 60 minutes. At this point, brains
were rapidly excised and sliced and bioluminescence
analysis was immediately performed. The highest pho-
ton emission was observed when the analysis was car-
ried out 20 minutes after the injection; after 40 or 60
minutes from the injection, bioluminescence was
found to be highly decreased in most brain areas, indi-
cating that luciferase substrate availability and enzyme
activity reach a plateau 15 to 20 minutes after sub-
strate injection (data not shown). On the basis of these
preliminary studies, all subsequent experiments were
carried out injecting 3 µL of 26.5 µg/µL luciferin solu-
tion ICV and euthanizing the mice 20 minutes later.
Photon Emission Measured by CCD Camera
Provides Data in Agreement with Standard
Enzymatic Assay Data
To test the extent to which photon emission measured
by CCD camera reflected a real change in the brain
content of luciferase enzymatic activity, we carried out
the measurements in parallel using one hemisphere of
the same brain for each technique. We analyzed the
brains of four groups of ERE-Luc male mice (treated
with 5, 20, and 50 µg/kg of E2 and corn oil as vehicle).
Animals were euthanized 6 hours after treatment, and
brains were sagittally halved: one half was sliced for
CCD camera bioluminescence analysis (Figure 5A),
whereas the other was processed for enzymatic assay.
The summation of the photons emitted by the sagittal
slices shows that luciferase activity increases in relation
to the dose of E2 administered (Figure 5B). This is con-
sistent with the study of luciferase enzymatic assay car-
ried out in the brain tissue extract (Figure 5C). The
extent of the increase observed with the two methods is
very similar (photon emission: + 77% cts/s; luciferase
enzymatic activity +82% RLU/µg of proteins).
This initial observation led us to conclude that ex
vivo imaging provides a measure of luciferase activity
as sensitive and quantitative as the biochemical study
of luciferase enzymatic activity. 
ER Antagonist ICI 182,780 Significantly Lowers
Brain Luciferase Activity
In previous experiments, brain luciferase activity in
intact male brains appeared to be high when compared
with peripheral tissues, where, in unstimulated males,
luciferase activity is at the lower limits of detection by
both imaging and biochemical assays.15 To establish
the extent to which photon emission measured in
brain sections was associated with the state of ER
transcriptional activity, male ERE-Luc mice were
treated with vehicle, the full ER antagonist ICI
182,780 (Fulvestrant, 1.3 µg/kg ICV), and the ER ago-
nist E2 (50 µg/kg, SC); animals were euthanized 6
hours after treatments, the time shown to induce the
highest response to E2 treatment by previous experi-
ments.15 In this set of experiments, we performed
coronal sections of the brains to facilitate the study of
the effect of the treatments in discrete brain regions.
Figure 1A shows a visible decrease in photon emission
in mice treated with ICI 182,780. The extent of the
decrease in photon emission in treated versus control
mice differed in each brain slice, with changes ranging
from –54% (slice 5) to –30% (slice 4). The average
decrease in whole brain was –44%. Thus, these data
suggest that in the absence of exogenous stimuli, ER in
the brain of adult male mice is transcriptionally active.
This was not surprising since it is well known that aro-
matase, the enzyme converting circulating testosterone
into E2, is widely expressed in the brain, and this
ensures a continuous, local synthesis of E2.23 In addi-
tion, the brain is rich in growth factors such as insulin-
like growth factor 1 or epidermal growth factor, which
have been described to transcriptionally activate the
unliganded receptor.24–26
In spite of the relatively high ER activity in the
intact mice, treatment with the natural hormone
induced a significant increase in slice bioluminescence
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(see Figure 1, A and B). The average increase in
luciferase activity in the 11 slices was +36% over con-
trols; the effect was highest in slice 3 (+64%), and no
significant effect was seen in slice 8.
To obtain a more detailed characterization of ER
activity in the central nervous system, we attempted
to measure photon emission in specific brain areas
identified by means of an electronic quantification
grid, created according to the Paxinos and Franklin
brain atlas (see Figure 1C).22 In unstimulated mice,
photon emission varied significantly among the differ-
ent brain areas taken into consideration, ranging from
a value of 2.8 to 4.7 counts/s/area unit (mm2); the
highest ER activity was found in the amygdala and
motor cortex and the lowest in the arcuate nucleus
(see Figure 1D). Interestingly, ICI 182,780 decreased
ER activity in all brain areas investigated with the
exception of piriform cortex and septal nuclei, where
the extent of the decrease did not reach a significant
value. The generalized decrease observed indicated
that the physiologic state of activity of ER in the brain
of intact males is sustained. E2 administration was
able to increase ER activity in the motor cortex
(+33%), piriform cortex (+50%), caudate putamen
(+28%), and thalamus (+23%).
We also measured luciferase enzymatic activity in
tissue extracts of some of the dissected brain areas and
obtained results superimposable to those shown above
(data not shown); however, the sensitivity of the enzy-
matic assay was not sufficient to study ER activity in
small brain nuclei such as arcuate or nucleus accum-
bens of single animals, thus pointing to the significant
advantage of using the imaging-based method.
Luciferase Content in Brain Reflects the
Fluctuating Production of Ovarian Hormones by
Adult Female ERE-Luc Mice
We then investigated the changes in photon emission
during the female estrous cycle. Female ERE-Luc mice
were daily subjected to vaginal lavages (see Figure 2A)
to assess the phase of the cycle; mice were euthanized
at the desired cycle phase, and brain bioluminescence
was measured. Quantitative analysis of photon emis-
sion recordings (see Figure 2, B and C) showed that in
selected brain areas, luciferase activity fluctuates with
the progression of the cycle. Consistent with the well-
known role of estrogens in the control of hypothalam-
ic and limbic functions, we observed high luciferase
activity at proestrus, the phase characterized by high
levels of circulating estrogens, and lower activity at
metestrus and diestrus. Figure 2 shows that in
proestrus, photon emission is significantly higher than
in diestrus in the hypothalamus (+60%), arcuate
(+105%), septum (+56%), and amygdala (+103%).
No significant change was observed in other areas
associated with the control of motor activities, such as
the caudate putamen. Similar to what was seen with
male mice, the brain area expressing the highest con-
tent of luciferase at all phases of the cycle was the
amygdala (higher than 5 cts/s/mm2).
These data demonstrate at the same time that the
new technique we developed is suitable to evaluate the
effects of physiologic changes of circulating E2.
ER Activation in Mammalian Brain of Males and
of Cycling Females
Previous studies,2,3 carried out by in situ hybridization
or by immunohistochemistry, failed to demonstrate
significant differences in ER expression in male and
female rodent brains. This prompted us to compare
the extent of luciferase activity observed in male and
female ERE-Luc brains.
In agreement with these findings, we failed to see sig-
nificant differences in luciferase activity in the two sexes
when we compared photon emissions from 11 brain
areas of males with emissions of females in diestrus.
However, significant differences were found by compar-
ing females in proestrus with intact males: in females in
proestrus, ER activity is significantly higher than in
males in the arcuate nucleus (+ 92%), thalamus (+
47%), septal nuclei (+ 56%), and hypothalamus (+
45%) (see Figure 3), indicating a higher plasticity of the
activity of these receptors in the female brain.
Discussion
The present study demonstrates that ERs localized in
both reproductive and nonreproductive areas of the
brain are transcriptionally active and susceptible to
regulation by estrogens. The study also shows, for the
first time, that the extent of ER activity in the brain of
unstimulated male and female mice is comparable and
quite elevated.27 This observation suggests that in
brain, the sex hormone receptor has functions that are
beyond the control of reproduction. Supporting this
view, the activity of ER is quite sustained in males and
females and is observed independently from the asso-
16 Stell et al
ciation of each given brain region to reproductive
functions. The finding of high ER activity in male
brain is not surprising in view of the widespread
expression of aromatase in this tissue; furthermore, we
believe that ligand-independent transcriptional activa-
tion of ER may occur, triggered by a crosstalk with
growth factors and other molecules inducing ER phos-
phorylation described by several laboratories, includ-
ing ours.15,24–26,28 The extent to which ER activity
changes in males in relation to the daily fluctuation of
testosterone remains to be established; on the other
hand, the study clearly shows the major influence of
the estrous cycle on ER activity in several brain areas:
the effect observed in limbic areas such as the hip-
pocampus is of particular interest with regard to the
alleged effects of estrogens on memory and affective
disorders. Interestingly, ER activity in the amygdala is
high in both sexes: this is consistent with the report
that ERs are most expressed in amygdaloid nuclei.4
Moreover, the present study exemplifies how the
technique we developed can provide substantial
advancement in our capabilities to study brain func-
tions. Prior to our study, attempts to elucidate the
potential role of ER and E2 in brain functions relied
mainly on in situ and immunohistochemical quantifi-
cation of ER messenger ribonucleic acid or proteins4,5;
however, the use of those techniques could not provide
clues on the dynamics of ER transcriptional activity.
Our method, on the contrary, offers a very sensitive,
reproducible, and accurate way to measure luciferase
activity in specific brain areas, enabling us to study the
dynamics of ER activity. 
The method can be easily expanded to the study of
brain activity of transcription factors, protein–protein
interaction, or neural cell differentiation or migration,
on availability of the suitable reporter animals. In
addition, the creation of suitable algorithms will
enable the generation of data banks where data can be
stored and repeatedly analyzed, thus facilitating com-
parative studies aimed at understanding the conse-
quences of pathophysiologic events on specific brain
functions and at evaluating the effects of pharmaco-
logic treatments in well-focused parts of the brain. The
main limitation of this technology is that it is not car-
ried out in living animals. Other laboratories, using
animal models aimed at showing more widespread
physiological changes (eg, glial fibrillary acidic pro-
tein–luciferase to study the inflammatory process),
demonstrated that the state of activation of astroglia
can be followed in living animals29: the resolution
achievable in these type of studies, even using instru-
mentation equipped for three-dimensional imaging, is,
however, still quite limited and does not allow us to
monitor changes at single brain nuclei level, as
described here. The rapidity of the evolution in the
field, however, leads us to hope that soon we will also
be able to study brain activities in living animals and
stimulates us to generate more and more sophisticated
animal models for in vivo imaging.
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Figure 4.  Assessment of luciferin concentration necessary for the
measurement of luciferase activity in mouse brain slices. A, Black-
and-white photograph of the sections numbered and exposed to a
charge-coupled device (CCD) camera and electronic grids generated
to delimit the areas to be used for photon emission counting.
Olfactory tubercles, dissected and located in the right end of the
middle row, were not taken into consideration in the present study.
B, Bioluminescence-based optical imaging of a representative brain
of ERE-Luc male mice after intracerebroventricular (ICV) injection
of 3 µL of a solution of 26.5 µg/µL luciferin; pseudocolors are rep-
resentative of the intensity of photon emission: the highest photon
emission is in white, and gradually lower emissions are in yellow,
red, green, and blue. C, Photon emission calculated as counts/second
of 11 brain sections of male ERE-Luc mice 20 minutes after ICV
injection of 3 µL of luciferin at different concentrations (8.8, 26.5,
and 79.7 µg/µL saline); the CCD camera exposure time was 15 min-
utes.
Figure 5.  Quantitative analysis of brain luciferase content as meas-
ured ex vivo by bioluminescence or enzymatic assay. The brains of
ERE-Luc adult male mice subcutaneously treated for 6 hours with
5, 20, and 50 µg/kg of E2 and corn oil as vehicle were excised: the
left hemisphere was isolated and sliced for optical imaging, and the
right hemisphere was used for the preparation of the extracts for the
biochemical assay of luciferase activity. A, Black-and-white photo-
graph and pseudocolor representative images of the four sagittal sec-
tions obtained from the left hemispheres. B, Photon emission, as
measured as counts/s, of the sagittal slices. The values in the graph
represent the summation of the photon emission from the four sagit-
tal slices. C, Luciferase activity measured in extracts from the entire
right hemisphere and expressed as relative light units (RLU)/µg of
proteins. The experiment was carried out in a group of four ERE-
Luc adult male mice. 
Figure 1. Effect of treatment with E2 and ICI 182,780 on photon
emission from ERE-Luc male brain. A, Optical imaging of represen-
tative brains of treated ERE-Luc mice. In the control group, animals
received corn oil subcutaneously (SC) as E2 vehicle and ethanol
intracerebroventricularly (ICV) as ICI vehicle; in the ICI group, mice
received corn oil SC and ICI 182,780 1.3 µg/kg ICV; in the E2
group, mice received E2 50 µg/kg SC and ethanol ICV. B,
Comparative analysis of photon emission in brain slices. Data are
expressed as the integration of the average photon emission unit
(Cts/s) and represent the mean ± SEM (n = 6–10). Statistical differ-
ences (*vehicle vs E2; °vehicle vs ICI) are reported: °/*p < .05;
°°/**p < .01; °°°/***p < .001. Statistical analysis is described in the
Methods section, where actual p values are listed. C, Electronic grid
delimiting specific brain areas to be used for photon emission count-
ing, created according to Paxinos and Franklin,22 superimposed to a
black-and-white photograph of brain sections. D, Comparative
analysis of photon emission in brain areas. Numbers on the x-axis
correspond to areas in C. Data are expressed as the average photon
emission in the area unit (cts/s/mm2) and represent the mean ± SEM
(n = 6–10). Statistical differences (*vehicle vs E2; °vehicle vs ICI) are
reported: °/*p < .05; °°/**p < .01; °°°/***p < .001. Statistical analy-
sis is described in the Methods section, where actual p values are
listed. See the text for abbreviations.
Figure 2.  Luciferase activity in the brain of intact, cycling ERE-Luc
adult female mice. A, Cytochemistry representative of vaginal
lavages stained at the different phases of the estrus cycle (D =
diestrus; E = estrus; M = miestrus; P = proestrus). B, Representative
optical imaging of female brain sections in each phase of the estrus
cycle. C, Photon emission in selected areas of female mouse brain.
Data represent the mean ± SEM of at least five animals/phase of the
cycle. Statistical analysis is described in the Methods section, where
actual p values are listed. See the text for abbreviations.
Figure 3.  Comparative analysis of luciferase expression in selected
brain areas of male and female ERE-Luc intact mice. Photon emis-
sion data obtained in the experiments described in Figure 1 and
Figure 2 were used to compare photon emission of male and female
brains. Numbers on the x-axis correspond to areas in Figure 1C.
Data are expressed as the average photon emission unit (cts/s/mm2)
and represent the mean ± SEM (n = 6–10 mice per group). Statistical
differences (*males vs female proestrus; °female diestrus vs female
proestrus) are reported: °/*p < .05; °°/**p < .01; °°°/***p < .001.
Statistical analysis is described in the Methods section, where actu-
al p values are listed. See the text for abbreviations.
